| Drug Report: IFEX (IFOSFAMIDE) | ||||||||
| Primary Suspect Reports: 1,467 Total Reports: 4,085 FDA AERS Reports from 11/01/1997 to 08/27/2012 | ||||||||
| Drug Description : | ||||||||
Ifex (ifosfamide) an anti-cancer chemotherapy drug used in combination with certain other drugs for the treatment of germ cell testicular cancer. It is used in conjunction with Mesnex (mesna) for hemorrhagic cystitis. Marketed by Bristol-Myers Squibb, Ifex was approved by the FDA on December 30, 1988. |
||||||||
| Other Names : | Generic Name : | Report Info: | ||||||
|
IFOSFAMIDE | Average Age: 39 Years |
||||||
FDA Listed Names (86) :
|
Manufacturer: | Common Conditions: | ||||||
(holoxan) |
Bristol-Myers Squibb Company (806) |
|
||||||
| Top IFEX Adverse Events/Side Effects |
|
|
|
| Side Effects MedDRA Preferred Terms |
IFEX Primary Suspect Reports | IFEX Total Reports |
ROR Score
|
PRR Score
|
Compare Top Drugs |
| Encephalopathy | 235 (16%) | 340 (8%) | Premium Feature | Premium Feature |
 |
| Confusional State | 148 (10%) | 207 (5%) | Premium Feature | Premium Feature |
|
| Thrombocytopenia | 93 (6%) | 285 (7%) | Premium Feature | Premium Feature |
|
| Neutropenia | 89 (6%) | 368 (9%) | Premium Feature | Premium Feature |
|
| Neurotoxicity | 85 (6%) | 133 (3%) | Premium Feature | Premium Feature |
|
| Vomiting | 78 (5%) | 209 (5%) | Premium Feature | Premium Feature |
|
| Leukopenia | 76 (5%) | 180 (4%) | Premium Feature | Premium Feature |
|
| Pyrexia | 75 (5%) | 272 (7%) | Premium Feature | Premium Feature |
|
| Anaemia | 74 (5%) | 173 (4%) | Premium Feature | Premium Feature |
|
| Febrile Neutropenia | 73 (5%) | 317 (8%) | Premium Feature | Premium Feature |
|
|
Data downloads, Grouping Adverse Events by different MedDRA levels and PRR/ROR calculations are reserved for our Premium Subscribers.
Click here to learn more about subscription levels and pricing. Click here to view a sample report that includes the premium sections. |
|||||
| Reported Report Outcomes for IFEX Adverse Events |
| Report Outcomes |
IFEX Primary Suspect (# of Reports) (11/01/1997 to 08/27/2012) |
IFEX Total (# of Reports) (11/01/1997 to 08/27/2012) |
| Hospitalization - Initial or Prolonged | 722 (49%) | 1,790 (44%) |
| Other | 582 (40%) | 1,645 (40%) |
| Death | 246 (17%) | 908 (22%) |
| Life-Threatening | 140 (10%) | 358 (9%) |
| Required Intervention to Prevent Permanent Impairment/Damage | 64 (4%) | 156 (4%) |
| Disability | 37 (3%) | 138 (3%) |
| Most Recent IFEX Report Reviews/FDA Reports (Primary Suspect) |
| Report Date | Age | Gender | Conditions | Adverse Events | Outcome |
| 08/16/2012 | 9 YR | F |
Cyst Nausea Rhabdomyosarcoma Show All |
Pulmonary Embolism Pulmonary Hypertension Cardiopulmonary Failure |
Death |
| 08/15/2012 | 68 YR | M |
Leiomyosarcoma Prophylaxis |
Metabolic Acidosis Sepsis Renal Failure Acute Show All |
Death Other |
| 08/15/2012 | 69 YR | F |
Diffuse Large B-cell Lymphoma Stage Iv |
Acute Myeloid Leukaemia |
Death Hospitalization - Initial or Prolonged |
| 08/14/2012 | 57 YR | F |
Ewing's Sarcoma |
Oedema Toxicity To Various Agents Tremor Show All |
Hospitalization - Initial or Prolonged |
| 08/13/2012 | 46 YR | F |
Ovarian Cancer |
Renal Tubular Necrosis Encephalopathy |
Death |
| 08/13/2012 | 54 YR | F |
Ovarian Cancer |
Renal Tubular Necrosis Encephalopathy |
Death |
| 07/25/2012 | 54 YR | M |
Sarcoma |
Glycosuria Electrolyte Imbalance Polyuria Show All |
Hospitalization - Initial or Prolonged |
| 07/19/2012 | 62 YR | F |
Sarcoma Metastatic |
Neurotoxicity Encephalopathy |
Other |
| 07/18/2012 | 62 YR | F |
Sarcoma Metastatic |
Encephalopathy |
Other |
| 07/16/2012 | 54 YR | M |
Sarcoma Metastatic |
Fanconi Syndrome Nephrogenic Diabetes Insipidus |
Hospitalization - Initial or Prolonged |
